The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

BACKGROUND: Major depressive disorder is among the most disabling illnesses worldwide, with a lifetime prevalence of 16.2%. Research suggests that 20% to 40% of patients with depression do not respond to pharmacotherapy, developing treatment-resistant depression. Electroconvulsive therapy is the gol...

Descripción completa

Detalles Bibliográficos
Autores principales: Knyahnytska, Yuliya, Zomorrodi, Reza, Kaster, Tyler, Voineskos, Daphne, Trevizol, Alisson, Blumberger, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804953/
https://www.ncbi.nlm.nih.gov/pubmed/34882570
http://dx.doi.org/10.2196/30163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804953/
https://www.ncbi.nlm.nih.gov/pubmed/34882570
http://dx.doi.org/10.2196/30163

Ejemplares similares